Peel Hunt restated their buy rating on shares of Motif Bio (LON:MTFB) in a research report sent to investors on Wednesday. Peel Hunt currently has a GBX 107 ($1.45) target price on the stock.

Several other research analysts have also recently commented on MTFB. Northland Securities reaffirmed a buy rating on shares of Motif Bio in a research report on Friday, September 29th. Beaufort Securities reaffirmed a speculative buy rating and issued a GBX 110 ($1.49) target price on shares of Motif Bio in a research report on Monday, October 2nd. Finally, FinnCap reaffirmed a buy rating and issued a GBX 100 ($1.36) target price on shares of Motif Bio in a research report on Wednesday, October 4th.

Shares of Motif Bio (LON:MTFB) traded up GBX 0.35 ($0.00) during mid-day trading on Wednesday, reaching GBX 41.10 ($0.56). The company had a trading volume of 608,849 shares, compared to its average volume of 886,306. The company has a market capitalization of $108.06 and a PE ratio of -152.22. Motif Bio has a 52-week low of GBX 22.50 ($0.31) and a 52-week high of GBX 51.75 ($0.70).

COPYRIGHT VIOLATION NOTICE: “Motif Bio’s (MTFB) Buy Rating Reiterated at Peel Hunt” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.dailypolitical.com/2018/01/14/motif-bios-mtfb-buy-rating-reiterated-at-peel-hunt.html.

About Motif Bio

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.